gutflix
GI learning, personalised

Summary

COMPARATIVE EFFICACY AND SAFETY OF BIOLOGIC THERAPIES IN ELDERLY AND YOUNGER PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Andreas N. Kapsoritakis

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A retrospective study of 187 IBD patients in Greece found comparable efficacy, safety, and drug sustainability of biologic therapies between patients over 60 years and younger patients.

KEY POINTS

- 267 IBD patients treated with biologics from 2010 to 2022 were screened and 187 were included, with 65% having Crohn's disease.
- Patients received infliximab (47.8%), adalimumab (18%), vedolizumab (18%), or ustekinumab (16%) with a median treatment duration of 10 years.
- Efficacy of biologic therapies did not differ significantly between patients aged over 60 years and younger patients.
- After adjusting for baseline characteristics, no significant differences in drug sustainability, time to adverse events, infection rates, or need for treatment optimization were found between elderly and younger patients ($p > 0.05$).
- The most common adverse events leading to drug discontinuation were loss of response and local injection site reactions.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/7fb7ef56-743c-11ee-80df-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.